Constellation Pharmaceuticals set terms for its planned initial public offering on Monday, saying it will offer 5.34 million shares priced at $14 to $16 each. The company would raise $80.1 million at the midpoint of the range. The clinical stage biotech, which is focusing on meeting unmet medial needs in patients with cancers caused by genetic flaws or drug resistance, is planning to list on Nasdaq, under the ticker symbol “CNST.” JP Morgan, Jefferies, BMO Capital Markets, and Oppenheimer & Co. are the underwriters of the deal.